Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 30, 2020 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the 9th Annual Glaucoma 360 New Horizons Forum and BIO CEO & Investor Forum

Long Beach, CA, Jan. 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
November 21, 2019 09:12 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Announces $2.0 Million Registered Direct Offering

Long Beach, CA, Nov. 21, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI) (“Emerald”), a biopharmaceutical company focused on bioengineered cannabinoid-based...
October 15, 2019 08:35 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience’s NB1111 Demonstrates Superiority in Lowering Intraocular Pressure Compared to Global Standard of Care Glaucoma Treatment in Preclinical Model

LONG BEACH, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global...
October 15, 2019 08:30 ET | Source: Emerald Bioscience, Inc.

Glauconix Presents Data Validating Impact of Emerald Bioscience’s Prodrug on the Ocular Endocannabinoid System in Glaucoma

Study Points to Unique Link Between the Endocannabinoid System and the Inflammatory Cascade in the Eye LONG BEACH, CA, Oct. 15, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc....
August 26, 2019 08:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience Appoints Chief Medical Officer and Executive Director, Clinical Operations

Long Beach, CA, Aug. 26, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
June 03, 2019 08:00 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Present at the 9th Annual LD Micro Invitational

LONG BEACH, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
May 13, 2019 08:00 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience to Participate at the CannaStocks 2019 Q1 Investor Conference

LONG BEACH, CA , May 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), focused on the development of cannabinoid-based therapeutics to address global medical...
April 01, 2019 07:30 ET | Source: Emerald Bioscience, Inc.

Emerald Bioscience, Inc. Announces DEA Decision that its Proprietary Cannabidiol Analog is not a Regulated Chemical or Controlled Substance Under Controlled Substances Act

LONG BEACH, CA, April 01, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Emerald Bioscience, Inc. (OTCQB: EMBI), a biopharmaceutical company focused on developing bioengineered cannabinoid-based...
March 25, 2019 08:00 ET | Source: Emerald Bioscience, Inc.

Nemus Bioscience, Inc. Changes Name to Emerald Bioscience, Inc. and Provides Update of Recent Research Accomplishments

Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...